OBJECTIVES: The purpose of this study was to identify important prognostic factors related to the status of a pancreatic tumor, its treatment, and the patient's general condition. METHODS: Between April 1992 and December 2006, 140 patients underwent a pancreatic resection for invasive ductal carcinoma. Prognostic factors were defined by univariate and multivariate analyses. RESULTS: The study included 103 tumors in the head of the pancreas and 37 tumors in the body or tail. The median survival time and the actuarial 5-year survival rate for all patients were 14.5 months and 12.3%, respectively. Using the significant prognostic factors identified by univariate analysis, multivariate analysis revealed that a preoperative serum CA19-9 concentration>100 U/ml (HR=1.84, p=0.0074), a tumor size>3 cm (HR=1.74, p=0.0235), venous involvement (HR=2.39, p=0.0006), a transfusion requirement of >or=1000 ml (HR=2.23, p=0.0006), and a serum albumin concentration on 1 postoperative month (1POM)<3 g/dl (HR=2.40, p=0.0009) were significant adverse prognostic factors. The presence of hypoalbuminemia on 1POM significantly correlated with a longer surgical procedure (p=0.0041), extended nerve plexus resection around the superior mesenteric artery (p=0.0456), and a longer postoperative hospital stay (p=0.0063). CONCLUSION: To improve long-term survival, preserving the patient's general condition by performing a curative resection with a short operation time and minimal blood loss should be the most important principle in the surgical treatment of pancreatic cancer.
OBJECTIVES: The purpose of this study was to identify important prognostic factors related to the status of a pancreatic tumor, its treatment, and the patient's general condition. METHODS: Between April 1992 and December 2006, 140 patients underwent a pancreatic resection for invasive ductal carcinoma. Prognostic factors were defined by univariate and multivariate analyses. RESULTS: The study included 103 tumors in the head of the pancreas and 37 tumors in the body or tail. The median survival time and the actuarial 5-year survival rate for all patients were 14.5 months and 12.3%, respectively. Using the significant prognostic factors identified by univariate analysis, multivariate analysis revealed that a preoperative serum CA19-9 concentration>100 U/ml (HR=1.84, p=0.0074), a tumor size>3 cm (HR=1.74, p=0.0235), venous involvement (HR=2.39, p=0.0006), a transfusion requirement of >or=1000 ml (HR=2.23, p=0.0006), and a serum albumin concentration on 1 postoperative month (1POM)<3 g/dl (HR=2.40, p=0.0009) were significant adverse prognostic factors. The presence of hypoalbuminemia on 1POM significantly correlated with a longer surgical procedure (p=0.0041), extended nerve plexus resection around the superior mesenteric artery (p=0.0456), and a longer postoperative hospital stay (p=0.0063). CONCLUSION: To improve long-term survival, preserving the patient's general condition by performing a curative resection with a short operation time and minimal blood loss should be the most important principle in the surgical treatment of pancreatic cancer.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Thomas J Howard; Joseph E Krug; Jian Yu; Nick J Zyromski; C Max Schmidt; Lewis E Jacobson; James A Madura; Eric A Wiebke; Keith D Lillemoe Journal: J Gastrointest Surg Date: 2006-12 Impact factor: 3.452
Authors: S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi Journal: Ann Surg Date: 1998-10 Impact factor: 12.969
Authors: Taylor S Riall; John L Cameron; Keith D Lillemoe; Kurtis A Campbell; Patricia K Sauter; JoAnn Coleman; Ross A Abrams; Daniel Laheru; Ralph H Hruban; Charles J Yeo Journal: J Gastrointest Surg Date: 2005-12 Impact factor: 3.267
Authors: Navid Farr; Yak-Nam Wang; Samantha D'Andrea; Frank Starr; Ari Partanen; Kayla M Gravelle; Jeannine S McCune; Linda J Risler; Stella G Whang; Amy Chang; Sunil R Hingorani; Donghoon Lee; Joo Ha Hwang Journal: Int J Hyperthermia Date: 2017-07-17 Impact factor: 3.914
Authors: Cynthia E Weber; Eileen A Bock; Michael G Hurtuk; Gerard J Abood; Jack Pickleman; Margo Shoup; Gerard V Aranha Journal: J Gastrointest Surg Date: 2013-11-23 Impact factor: 3.452
Authors: Saboor Khan; Guido Sclabas; Kaye Reid-Lombardo; Michael G Sarr; David Nagorney; Michael L Kendrick; Florencia G Que; John H Donohue; Marianne Huebner; Christine Lohse; Michael B Farnell Journal: J Gastrointest Surg Date: 2010-07-30 Impact factor: 3.452
Authors: James R Butler; Syed A Ahmad; Matthew H Katz; Jessica L Cioffi; Nicholas J Zyromski Journal: HPB (Oxford) Date: 2016-02-01 Impact factor: 3.647
Authors: Imran Bhatti; Oliver Peacock; Altaf K Awan; David Semeraro; Michael Larvin; Richard I Hall Journal: World J Surg Date: 2010-04 Impact factor: 3.352
Authors: Vegard Tjomsland; Per Sandström; Anna Spångeus; Davorka Messmer; Johan Emilsson; Ursula Falkmer; Sture Falkmer; Karl-Eric Magnusson; Kurt Borch; Marie Larsson Journal: BMC Cancer Date: 2010-03-09 Impact factor: 4.430